Page 136 - 南京医科大学自然版

第46卷第7期
·1082 · 南 京 医 科 大 学 学 报 2026年7月

设计与指导，经费支持。 Cochrane Database Syst Rev，2024，8（8）：CD015495
Author’s Contributions： ［10］QU F J，ZHOU Y，WU S. Progress of immune checkpoint

KONG Ziyue was responsible for literature retrieval and pa⁃ inhibitors therapy for non⁃small cell lung cancer with liv⁃
per writing. MA Xiao was responsible for data analysis；KONG er metastases［J］. Br J Cancer，2024，130（2）：165-175
Ziyue，WEI Chenchen，and LU Binbin collected the clinical ［11］TACHIBANA Y，MORIMOTO K，YAMADA T，et al.
data；WANG Zhaoxia was responsible for the design and guid⁃ Depth of response and treatment outcomes of immune
ance of the project，and financial support. checkpoint inhibitor ⁃ based therapy in patients with ad⁃
vanced non⁃small cell lung cancer and high PD⁃L1 ex⁃
［参考文献］
pression：an exploratory analysis of retrospective multi⁃
［1］ BRAY F，LAVERSANNE M，SUNG H，et al. Global cancer
center cohort［J］. Invest New Drugs，2024，42（5）：538-
statistics 2022：GLOBOCAN estimates of incidence and
546
mortality worldwide for 36 cancers in 185 countries［J］.
［12］SONG K，LEE H W，CHOI H S，et al. Comparison of the
CA Cancer J Clin，2024，74（3）：229-263
modified TyG indices and other parameters to predict non⁃
［2］ LAHIRI A，MAJI A，POTDAR P D，et al. Lung cancer im⁃
alcoholic fatty liver disease in youth［J］. Biology，2022，11
munotherapy：progress，pitfalls，and promises［J］. Mol
（5）：685
Cancer，2023，22（1）：40
［13］YAO Z Y，MA X，CUI Y Z，et al. Impact of triglyceride⁃
［3］ ZHOU S J，XIE J J，HUANG Z Q，et al. Anti⁃PD⁃（L） 1 im⁃
glucose index on the long⁃term prognosis of advanced gas⁃
munotherapy for brain metastases in non⁃small cell lung
tric cancer patients receiving immunotherapy combined
cancer：Mechanisms，advances，and challenges［J］. Can⁃ with chemotherapy［J］. World J Gastroenterol，2025，31
cer Lett，2021，502：166-179 （5）：102249
［4］ PANG L L，GAN J D，HUANG Y H，et al. Role of antian⁃ ［14］TAO S Y，YU L T，LI J，et al. Multiple triglyceride⁃de⁃
giogenic agents in first ⁃ line treatment for advanced rived metabolic indices and incident cardiovascular out⁃
NSCLC in the era of immunotherapy［J］. BMC Cancer， comes in patients with type 2 diabetes and coronary heart
2023，23（1）：72 disease［J］. Cardiovasc Diabetol，2024，23（1）：359
［5］ SIVORI S，VACCA P，DEL ZOTTO G，et al. Human NK ［15］XIAO Y，WANG H，TANG Y，et al. Increased risk of dia⁃
cells：surface receptors，inhibitory checkpoints，and trans⁃ betes in cancer survivors：a pooled analysis of 13 popula⁃
lational applications［J］. Cell Mol Immunol，2019，16（5）： tion⁃based cohort studies［J］. ESMO Open，2021，6（4）：
430-441 100218
［6］ WU Y L，ZHANG L，FAN Y，et al. Randomized clinical ［16］FRITZ J，BJØRGE T，NAGEL G，et al. The triglyceride⁃
trial of pembrolizumab vs. chemotherapy for previously un⁃ glucose index as a measure of insulin resistance and risk
treated Chinese patients with PD⁃L1⁃positive locally ad⁃ of obesity⁃related cancers［J］. Int J Epidemiol，2020，49
vanced or metastatic non⁃small⁃cell lung cancer：KEY⁃ （1）：193-204
NOTE⁃042 China Study［J］. Int J Cancer，2021，148（9）： ［17］MARTINI A，SHAH Q N，WAINGANKAR N，et al. The
2313-2320 obesity paradox in metastatic castration⁃resistant prostate
［7］ RECK M，RODRÍGUEZ⁃ABREU D，ROBINSON A G，et cancer［J］. Prostate Cancer Prostatic Dis，2022，25（3）：
al. Five⁃year outcomes with pembrolizumab versus chemo⁃ 472-478
therapy for metastatic non⁃small⁃cell lung cancer with PD⁃ ［18］YI M，ZHENG X L，NIU M K，et al. Combination strate⁃
L1 tumor proportion score ≥ 50［J］. J Clin Oncol，2021， gies with PD⁃1/PD⁃L1 blockade：current advances and fu⁃
39（21）：2339⁃2349 ture directions［J］. Mol Cancer，2022，21（1）：28
［8］ TANAKA H，MAKIGUCHI T，TOZUKA T，et al. Compari⁃ ［19］GARASSINO M C，GADGEEL S，ESTEBAN E，et al. Pa⁃
son of immune checkpoint inhibitor plus chemotherapy or tient⁃reported outcomes following pembrolizumab or pla⁃
ipilimumab plus nivolumab⁃based therapy for NSCLC pa⁃ cebo plus pemetrexed and platinum in patients with previ⁃
tients with PD⁃L1 TPS（1⁃49%）：TOPGAN2023⁃01［J］. ously untreated，metastatic，non⁃squamous non⁃small⁃cell
Eur J Cancer，2024，213：115117 lung cancer（KEYNOTE ⁃ 189）：a multicentre，double ⁃
［9］ ORILLARD E，ADHIKARI A，MALOUF R S，et al. Im⁃ blind，randomised，placebo⁃controlled，phase 3 trial［J］.
mune checkpoint inhibitors plus platinum⁃based chemo⁃ Lancet Oncol，2020，21（3）：387-397
therapy compared to platinum ⁃ based chemotherapy with ［20］EMANCIPATOR K. Keytruda and PD⁃L1：a real⁃world ex⁃
or without bevacizumab for first ⁃ line treatment of older ample of co⁃development of a drug with a predictive bio⁃
people with advanced non ⁃ small cell lung cancer［J］. （下转第1112页）